Medical Irradiation Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The medical irradiation market size has grown rapidly in recent years. It will grow from $1.69 billion in 2024 to $1.97 billion in 2025 at a compound annual growth rate (CAGR) of 16.7%. The growth in the historic period can be attributed to increasing prevalence of cancer, growing adoption of radiation therapy, rising geriatric population, increasing demand for non-invasive treatment options, and expansion of healthcare infrastructure.

The medical irradiation market size is expected to see rapid growth in the next few years. It will grow to $3.33 billion in 2029 at a compound annual growth rate (CAGR) of 14.1%. The growth in the forecast period can be attributed to government initiatives to improve cancer care, growing awareness about early detection and treatment, rising disposable income, increasing focus on precision medicine, and rising demand for targeted cancer therapies. Major trends in the forecast period include integration of artificial intelligence in radiation therapy, online adaptive radiotherapy, popularity of hypo fractionated radiation therapy, proton therapy for precise cancer treatment, and shift towards image-guided radiation therapy (IGRT).

The increasing prevalence of cancer is expected to drive the growth of the medical irradiation market in the coming years. Cancer is characterized by uncontrolled cell growth, affecting various organs and leading to significant morbidity and mortality globally. Medical irradiation plays a vital role in cancer treatment, using targeted radiation to damage or destroy cancer cells while minimizing harm to healthy tissues. For example, a report by the Leukemia & Lymphoma Society, a US-based non-profit health organization, predicts that in 2023, 184,720 individuals in the US will be diagnosed with leukemia, lymphoma, or myeloma. Additionally, approximately 1,958,310 new cancer cases are expected to be diagnosed in the US in 2023, with leukemia, lymphoma, and myeloma accounting for 9.4% of those cases. As a result, the high incidence of cancer is fueling the growth of the medical irradiation market.

Major companies operating in the medical irradiation market are developing innovative solutions, such as the Premium Dual-Energy Mobile System, to gain a competitive advantage. A Premium Dual-Energy Mobile System is a high-end medical imaging device that integrates dual-energy technology for enhanced diagnostic capabilities while offering mobility across different clinical settings, providing advanced imaging solutions at the point of care. For instance, in July 2023, KA Imaging, a Canada-based manufacturer, unveiled its Reveal Mobi Pro dual-energy mobile X-ray system. The Reveal Mobi Pro is a comprehensive mobile X-ray solution that combines SpectralDR technology with KA Imaging's Reveal 35C detector. At the bedside, Reveal's capacity to take dual-energy and conventional images simultaneously with a single exposure enhances patient and hospital results while safeguarding income by lowering outflows.

In October 2022, Halma plc, a UK-based technology company, acquired IZI medical products for £138 million ($146 million). Through the acquisition, Halma aims to diversify its portfolio of physician-led innovations, enhancing its ability to meet patient demands and deliver high-quality healthcare services. IZI Medical Products is a US-based manufacturer of radiation therapy, diagnostic radiology, and image-guided surgery medical devices.

Major companies operating in the medical irradiation market are Hitachi Ltd., Thermo Fisher Scientific Inc., Toshiba Corporation, Siemens Healthcare GmbH, Koninklijke Philips N.V., GE Healthcare Company, Mayo Clinic Health System, Canon Medical Systems R&D (Dalian) Co. Ltd., PerkinElmer Inc., Varian Medical Systems Inc., Elekta AB, Accuray Incorporated, Ion Beam Applications S.A., Brainlab AG, ViewRay Technologies Inc., Mevion Medical Systems Inc., RaySearch Laboratories AB, NTP Radioisotopes SOC Ltd., RefleXion Medical Inc., Vision RT Ltd., Sun Nuclear Corporation, IZI Medical Products LLC, Eckert & Ziegler BEBIG GmbH, C-RAD AB, Panacea Medical Technologies Pvt. Ltd., Standard Imaging Inc., CIVCO Radiotherapy Inc., IntraOp Medical Corporation, RTsafe Solutions Ltd., ASG Superconductors S.p.A., Mirada Medical Corporation.

North America was the largest region in the medical irradiation market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the medical irradiation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the medical irradiation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The medical irradiation market includes revenues earned by entities by providing services such as diagnostic imaging services, radiation therapy, radiopharmaceutical and radiation safety, and dosimetry services. The market value includes the value of related goods sold by the service provider or included within the service offering. The medical irradiation market consists of sales of products such as radiation therapy equipment, diagnostic imaging devices, radiopharmaceuticals, and nuclear medicine devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

Medical irradiation refers to the targeted use of radiation in treating diseases, particularly cancer, where controlled doses are applied to damage or destroy specific cells while minimizing their impact on healthy tissues. It is employed in diagnostic settings to produce images of internal structures or functions, facilitating the identification and diagnosis of various medical conditions.

The disease types of medical irradiation include trisomy 21, translocation medical irradiation, and mosaic medical irradiation. Trisomy 21 is a genetic condition characterized by the presence of an extra copy of chromosome 21, leading to Down syndrome. The treatment types are categorized into two categories such as diagnosis and therapy. The distribution channels include direct tenders, retail sales, and others. The end users are hospitals, clinics, homecare settings, therapy centers, and others.

The disease types of medical irradiation include trisomy 21, translocation medical irradiation, and mosaic medical irradiation. Trisomy 21 is a genetic condition characterized by the presence of an extra copy of chromosome 21, leading to Down syndrome. The treatment types are categorized into two categories such as diagnosis and therapy. The distribution channels include direct tenders, retail sales, and others. The end users are hospitals, clinics, homecare settings, therapy centers, and others.

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.